932 related articles for article (PubMed ID: 17689367)
1. Minimal uptake of sterile drug preparation equipment in a predominantly cocaine injecting population: implications for HIV and hepatitis C prevention.
Morissette C; Cox J; De P; Tremblay C; Roy E; Allard R; Stephenson R; Graves L
Int J Drug Policy; 2007 May; 18(3):204-12. PubMed ID: 17689367
[TBL] [Abstract][Full Text] [Related]
2. Changes in injecting practices associated with the use of a medically supervised safer injection facility.
Stoltz JA; Wood E; Small W; Li K; Tyndall M; Montaner J; Kerr T
J Public Health (Oxf); 2007 Mar; 29(1):35-9. PubMed ID: 17229788
[TBL] [Abstract][Full Text] [Related]
3. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews.
Palmateer N; Kimber J; Hickman M; Hutchinson S; Rhodes T; Goldberg D
Addiction; 2010 May; 105(5):844-59. PubMed ID: 20219055
[TBL] [Abstract][Full Text] [Related]
4. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
Vicknasingam B; Narayanan S; Navaratnam V
Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801
[TBL] [Abstract][Full Text] [Related]
5. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003.
Emmanuelli J; Desenclos JC
Addiction; 2005 Nov; 100(11):1690-700. PubMed ID: 16277629
[TBL] [Abstract][Full Text] [Related]
6. Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention.
Koester S; Glanz J; Barón A
AIDS Behav; 2005 Mar; 9(1):27-39. PubMed ID: 15812611
[TBL] [Abstract][Full Text] [Related]
7. Syringe exchanges: a public health response to problem drug use.
Cox GM; Lawless MC; Cassin SP; Geoghegan TW
Ir Med J; 2000; 93(5):143-6. PubMed ID: 11072923
[TBL] [Abstract][Full Text] [Related]
8. "I inject less as I have easier access to pipes": injecting, and sharing of crack-smoking materials, decline as safer crack-smoking resources are distributed.
Leonard L; DeRubeis E; Pelude L; Medd E; Birkett N; Seto J
Int J Drug Policy; 2008 Jun; 19(3):255-64. PubMed ID: 18502378
[TBL] [Abstract][Full Text] [Related]
9. Use of supervised injection facilities and injection risk behaviours among young drug injectors.
Bravo MJ; Royuela L; De la Fuente L; Brugal MT; Barrio G; Domingo-Salvany A;
Addiction; 2009 Apr; 104(4):614-9. PubMed ID: 19215603
[TBL] [Abstract][Full Text] [Related]
10. [Prevalence of human immunodeficiency virus and hepatitis C virus, and associated factors among injecting drug users in Catalonia].
Huntington S; Folch C; González V; Meroño M; Ncube F; Casabona J
Enferm Infecc Microbiol Clin; 2010 Apr; 28(4):236-8. PubMed ID: 19695744
[TBL] [Abstract][Full Text] [Related]
11. Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning.
Wand H; Spiegelman D; Law M; Jalaludin B; Kaldor J; Maher L
Addiction; 2009 Dec; 104(12):2049-56. PubMed ID: 19804463
[TBL] [Abstract][Full Text] [Related]
12. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users.
Van Den Berg C; Smit C; Van Brussel G; Coutinho R; Prins M;
Addiction; 2007 Sep; 102(9):1454-62. PubMed ID: 17697278
[TBL] [Abstract][Full Text] [Related]
13. Irish injecting drug users and hepatitis C: the importance of the social context of injecting.
Smyth BP; Barry J; Keenan E
Int J Epidemiol; 2005 Feb; 34(1):166-72. PubMed ID: 15513970
[TBL] [Abstract][Full Text] [Related]
14. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia.
Maher L; Jalaludin B; Chant KG; Jayasuriya R; Sladden T; Kaldor JM; Sargent PL
Addiction; 2006 Oct; 101(10):1499-508. PubMed ID: 16968352
[TBL] [Abstract][Full Text] [Related]
16. Client satisfaction and risk behaviours of the users of syringe dispensing machines: a pilot study.
Islam M; Stern T; Conigrave KM; Wodak A
Drug Alcohol Rev; 2008 Jan; 27(1):13-9. PubMed ID: 18034377
[TBL] [Abstract][Full Text] [Related]
17. New syringe acquisition and multi-person use of syringes among illegal drug users.
Richard AJ; Mosier V; Atkinson JS
J Public Health Policy; 2002; 23(3):324-43. PubMed ID: 12325289
[TBL] [Abstract][Full Text] [Related]
18. A syringe exchange programme in prison as prevention strategy against HIV infection and hepatitis B and C in Berlin, Germany.
Stark K; Herrmann U; Ehrhardt S; Bienzle U
Epidemiol Infect; 2006 Aug; 134(4):814-9. PubMed ID: 16371183
[TBL] [Abstract][Full Text] [Related]
19. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users.
Miller CL; Johnston C; Spittal PM; Li K; Laliberté N; Montaner JS; Schechter MT
Hepatology; 2002 Sep; 36(3):737-42. PubMed ID: 12198668
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty.
Rhodes T; Davis M; Judd A
Addiction; 2004 May; 99(5):621-33. PubMed ID: 15078237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
